Merck says research shows its COVID-19 pill works against variants

Image: The Merck & Co campus in Rahway, New Jersey, U.S. REUTERS/Brendan McDermid

Sept 29 (Reuters) – Laboratory studies show that Merck & Co’s (MRK.N) experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, including the dominant, highly transmissible Delta, the company said on Wednesday.

Since molnupiravir does not target the spike protein of the virus – the target of all current COVID-19 vaccines – which defines the differences between the variants, the drug should be equally effective as the virus continues to evolve, said Jay Grobler, head of infectious disease and vaccines at Merck.

Molnupiravir instead targets the viral polymerase, an enzyme needed for the virus to make copies of itself. It is designed to work by introducing errors into the genetic code of the virus.

Data shows that the drug is most effective when given early in the course of infection, Merck said.

The U.S. drugmaker tested its antiviral against nasal swab samples taken from participants in early trials of the drug. Delta was not in wide circulation at the time of those trials, but molnupiravir was tested against lab samples of the variant behind the latest surge in COVID-19 hospitalizations and deaths.

Merck said earlier this year that a small, mid-stage trial found that after five days of molnupiravir treatment, none of the patients taking various doses of the drug tested positive for infectious virus, while 24% of placebo patients did have detectable levels.

An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS

Merck is currently conducting two Phase III trials of the antiviral it is developing with Ridgeback Biotherapeutics – one for treatment of COVID-19 and another as a preventive.

Merck anticipates that the Phase III treatment study will finish in early November, Grobler said.

The trial enrolled nonhospitalized COVID-19 patients who have had symptoms for no more than five days and are at risk for severe disease.

The latest analysis was presented during IDWeek, the annual meeting of infectious disease organizations, including the Infectious Diseases Society of America.

Shares of Merck were up 2.3% at $75.04 on Wednesday afternoon on the New York Stock Exchange.

 

Source: Reuters

About STELLAPHARM

Stellapharm is one of leading generics pharmaceutical companies and strong producer of anti-viral drugs in Vietnam. The company established in Vietnam in 2000; and focuses on both prescription drugs and non-prescription especially in cardiovascular diseases, antiviral drugs, anti-diabetics drugs, etc. and our products are now used by millions of patients in more than 50 countries worldwide.

The company is globally recognized for its quality through our facilities have been audited and approved by stringent authority like EMA, PMDA, Taiwan GMP, local WHO and others.

Additional information for this article: Stellapharm J.V. Co., Ltd. – Branch 1
A: 40 Tu Do Avenue, Vietnam – Singapore Industrial Park, An Phu Ward, Thuan An City, Binh Duong Province, Vietnam
T: +84 274 376 7470 | F: +84 274 376 7469 | E: info@stellapharm.com | W: www.stellapharm.com

You May like

18 Oct 2021

Will New Covid Treatments Be as Elusive for Poor Countries as Vaccines?

By Stephanie NolenOct. 17, 2021 Merck has taken a step to make its antiviral pill available in poor nations, but many obstacles remain for broad access to coronavirus drugs. Nearly a year after the first Covid-19 vaccination campaigns began, the vast majority of the shots have gone to people in wealthy nations, with no clear

17 Oct 2021

Countries in Asia are placing orders for a new drug to treat coronavirus. Poorer nations could miss out again

(CNN)During the global scramble to secure vaccines, many countries in Asia-Pacific were slow off the mark. This time, they’re not making the same mistake.Countries around the region are rushing to place orders for the latest weapon against Covid-19: an antiviral pill that isn’t even authorized for use yet. Molnupiravir — produced by US pharmaceutical company